Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
16 févr. 2021 16h45 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market
01 févr. 2021 17h16 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Reports Third Quarter 2020 Financial Results
12 nov. 2020 16h25 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...
Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering
28 oct. 2020 17h54 HE
|
Cancer Genetics, Inc.
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology services,...
Cancer Genetics and StemoniX Announce Joint Proof-of-Concept Program
03 sept. 2020 08h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., and MAPLE GROVE, MN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and...
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
24 juin 2020 17h30 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
01 juin 2020 08h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial...
Cancer Genetics Issues Letter to Shareholders
20 févr. 2020 09h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and immuno-oncology...
Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update
20 nov. 2019 08h00 HE
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic,...